QNCX - Quince Therapeutics, Inc.

1.27
-0.100   -7.874%

Share volume: 1,707,213
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$1.37
-0.10
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 37%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.22%
1 Month
1,150.00%
3 Months
-60.92%
6 Months
-30.22%
1 Year
20.95%
2 Year
19.81%
Key data
Stock price
$1.27
P/E Ratio 
0.00
DAY RANGE
$1.23 - $1.41
EPS 
-$1.21
52 WEEK RANGE
$0.08 - $4.55
52 WEEK CHANGE
$20.95
MARKET CAP 
87.553 M
YIELD 
N/A
SHARES OUTSTANDING 
55.681 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
-0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,824,458
AVERAGE 30 VOLUME 
$116,872,048
Company detail
CEO: Dirk Thye
Region: US
Website: quincetx.com
Employees: 60
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.

Recent news